CompanyIMUXNasdaqNew York, X1

Immunic AG

Immunic develops oral small molecules for neurologic diseases.

SEC EDGAR ClinicalTrials.gov imux.com

8-KSep 11Latest SEC filing, period to Sep 10

Aug 11Latest story

August 2026

Immunic adds Elena Ridloff to board ahead of Phase 3 MS readout

Aug 11PeopleImmunic AG

July 2026

Immunic board adds CEO Erik Lundgren as director after Tamar Howson's retirement

Jul 6PeopleImmunic AG